ⅢA(N_(2))期非小细胞肺癌辅助放疗疗效影响因素的研究进展  

Research progress on efficacy and influencing factors of postoperative radiotherapy for stageⅢA(N_(2))non-small cell lung cancer

作　　者：凌丽仙 傅健飞[1] Ling Lixian;Fu Jianfei(Department of Medical Oncology,Affiliated Jinhua Hospital,Zhejiang University School of Medicine,Jinhua 321000,China)

机构地区：[1]浙江大学医学院附属金华医院肿瘤内科,金华321000

出　　处：《中华放射肿瘤学杂志》2022年第10期944-948,共5页Chinese Journal of Radiation Oncology

基　　金：金华市中心医院中青年科研启动基金(2021-4-040)。

摘　　要：非小细胞肺癌(NSCLC)恶性程度很高,预后差。其中,ⅢA(N_(2))期约占20%,此分期患者异质性大,生存差异明显,局部复发及远处转移是其治疗失败的主要原因。目前,对于辅助放疗用于治疗ⅢA(N_(2))期NSCLC患者仍存在争议,ⅢA(N_(2))期NSCLC患者行辅助放疗尚缺乏高级别证据。Non-small cell lung cancer(NSCLC)is highly malignant and has poor prognosis,in which stageⅢA(N_(2))NSCLC approximately accounts for 20%.Patients with stageⅢA(N_(2))NSCLC have high heterogeneity and distinct survival difference.Loco-regional recurrence and distant metastasis are the main causes of treatment failure.At present,whether stageⅢA(N_(2))NSCLC patients should receive postoperative radiotherapy(PORT)remains controversial.Such patients still lack high level proof to receive PORT.

关 键 词：癌 非小细胞肺 ⅢA(N_(2))期 辅助放射疗法 研究进展 

分 类 号：R734.2[医药卫生—肿瘤]